What Is 22q11.2 deletion syndrome

Overview

22q10.2 deletion syndrome, also known as DiGeorge syndrome or velocardiofacial syndrome, is one of the most common microdeletion disorders in humans. It results from a missing segment on the long arm of chromosome 22, specifically at the q11.2 location, which disrupts normal embryonic development.

The syndrome affects multiple body systems, leading to a wide range of physical, cognitive, and medical challenges. Because symptoms vary significantly, diagnosis often occurs later in childhood or even in adulthood, despite the condition being present from birth.

• Chromosome 22: The deletion occurs on the long arm of chromosome 22 at band q11.2, removing a segment of approximately 1.5 to 3 million base pairs that includes 30 to 40 genes.
• Incidence: It occurs in about 1 in 4,000 live births, making it one of the most common chromosomal deletion syndromes, though some estimates suggest it may be as frequent as 1 in 2,000.
• Gene loss: The TBX1 gene is considered a major contributor to physical symptoms, including heart defects and facial abnormalities, due to its role in pharyngeal arch development.
• Variable expression: No two individuals have the same symptom profile—some may have mild learning issues, while others face life-threatening heart defects or immune deficiencies.
• Associated names: The condition has been historically called DiGeorge syndrome, velocardiofacial syndrome (VCFS), and conotruncal anomaly face syndrome, now unified under 22q11.2 deletion syndrome.

How It Works

The deletion at 22q11.2 disrupts normal gene function during early fetal development, particularly affecting structures derived from the third and fourth pharyngeal pouches. This leads to malformations in the heart, face, thymus, and parathyroid glands, as well as neurodevelopmental differences.

• Deletion mechanism:90% of cases involve a 3 megabase deletion, while about 8% have a smaller 1.5 Mb deletion; both remove critical developmental genes.
• Inheritance pattern: Though usually de novo (new in the individual), it follows an autosomal dominant pattern, meaning a 50% chance of passing it to offspring if a parent is affected.
• Diagnostic methods:FISH testing was historically used, but chromosomal microarray is now the gold standard for detecting the microdeletion with high accuracy.
• Facial features: Common traits include hooded eyelids, a long face, small ears, and a tubular nose, though these may become less noticeable with age.
• Immune deficiency: Due to thymic hypoplasia, up to 75% of infants have reduced T-cell production, increasing susceptibility to infections.
• Neuropsychiatric risks: By adulthood, 25% to 30% of individuals develop schizophrenia or schizoaffective disorder, significantly higher than the general population.

Comparison at a Glance

Below is a comparison of 22q11.2 deletion syndrome with other common genetic disorders based on prevalence, genetic cause, and key features.

While 22q11.2 deletion syndrome shares features like congenital heart disease with other conditions, its unique genetic cause and variable expression require targeted diagnostic and management approaches. Early identification enables proactive treatment of immune, endocrine, and developmental issues.

Why It Matters

Understanding 22q11.2 deletion syndrome is critical for early intervention, improving long-term outcomes through coordinated, multidisciplinary care. Despite its frequency, it remains underdiagnosed, leading to delayed support for affected individuals and families.

• Early diagnosis: Identifying the syndrome in infancy allows for proactive screening of heart defects, calcium levels, and immune function, preventing life-threatening complications.
• Developmental support: Up to 80% of children have developmental delays, requiring speech, occupational, and educational interventions from an early age.
• Mental health: The high risk of anxiety, ADHD, and psychosis in adolescence and adulthood necessitates regular psychiatric monitoring and support.
• Medical management: Correcting hypocalcemia due to parathyroid issues and managing congenital heart defects surgically can significantly improve quality of life.
• Family planning: Genetic counseling is essential, as each child of an affected parent has a 50% chance of inheriting the deletion.
• Research impact: Studying 22q11.2 helps scientists understand gene-brain connections, particularly in schizophrenia and autism spectrum disorders.

With growing awareness and improved genetic testing, more individuals are being diagnosed earlier, enabling better health outcomes and support across the lifespan.